CRO market seen hitting $170.6B by 2035

The global contract research organization market is projected to nearly double to $170.63 billion by 2035 from $89.88 billion in 2025, driven by more pharma outsourcing, AI-enabled trials and growth in Asia-Pacific. The forecast points to rising demand for outsourced clinical development as drugmakers seek speed, flexibility and specialized expertise.

Why it matters: - Contract research organizations are becoming a bigger part of how drugs are developed, especially as pharma and biotech companies outsource more of the clinical trial process. - The market's projected rise to $170.63 billion by 2035 signals sustained demand for outsourced research, trial management and regulatory support. - The shift matters for drugmakers because it can lower fixed costs, speed development and expand access to specialized capabilities.

What happened: - Market Research Future projected the global Contract Research Organization market at $89.88 billion in 2025 and $170.63 billion by 2035. - The forecast implies a 6.62% compound annual growth rate from 2025 to 2035. - The market base was estimated at $84.3 billion in 2024. - The forecast was released Aug. 21, 2026. - A free sample and the full report are available through the company's sample request page and the detailed report.

The details: - Pharma and biotech sponsors are outsourcing more clinical trials and development work to CROs to gain specialized expertise, faster execution and operational flexibility. - Artificial intelligence, machine learning and decentralized trial technologies are reducing recruitment time, improving data quality and lowering protocol amendment rates. - Clinical research is spreading farther into Asia-Pacific and other emerging markets because of large treatment-naive patient pools, lower operating costs and regulatory harmonization. - Peer-reviewed analysis of the WHO International Clinical Trials Registry Platform found nearly 700,000 clinical trials registered globally since 2005, including more than 478,000 interventional trials. - The WHO registry includes more than 17,000 currently active clinical trials. - Pharmaceutical R&D spending is projected to exceed $200 billion annually by 2026. - Full-service CROs accounted for about 61% of service revenue. - Pharmaceutical companies made up nearly 64% of end-use demand. - Oncology held about 42% of therapeutic-area share. - Phase III studies accounted for about 53% of phase share. - North America held more than 44.96% of global revenue in 2024, equal to about $37.9 billion. - Europe was the second-largest regional market at about $21.075 billion in 2024. - Asia-Pacific held about 10% share and is growing rapidly. - The Middle East and Africa held a 4.3% share. - South America is emerging as a growth region, led by Brazil and Argentina.

Between the lines: - The forecast suggests CRO growth is being driven by structural changes in drug development, not a short-term cycle. - The strongest competitive edge is shifting toward firms that combine global site reach with technology, therapeutic depth and compliance expertise. - The market is becoming more specialized as trial complexity rises in oncology, cell and gene therapy, rare disease and other high-cost programs. - Regulatory pressure is also raising the value of CROs that can manage quality systems and inspection readiness across multiple jurisdictions.

What's next: - CRO demand is likely to keep rising as sponsors expand outsourcing in late-stage trials, laboratory services and real-world evidence generation. - Decentralized and hybrid trial models are expected to keep gaining traction as regulators support remote and patient-centric study designs. - More consolidation and partnerships are likely as major CROs buy specialized capabilities and expand regional footprints. - Market Research Future also pointed readers to related research on vaccine, influenza vaccination, pediatric vaccines, human vaccines, recombinant vaccines, immunotherapy drugs, infectious disease treatments and biopharmaceuticals.

The bottom line: - The CRO market is moving from a support function to a core part of drug development, and the forecast shows that outsourcing, digital tools and global trial expansion are now long-term growth engines.